Opinion|Videos|November 19, 2026

Prostate Cancer, BPH, and Testosterone Scheduling Myths

Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.

This episode, titled ‘Prostate Cancer, BPH, and Testosterone Scheduling Myths,’ features panelists Abraham Morgentaler, MD, FACS; Mohit Khera, MD, MBA, MPH; and Helen L. Bernie, DO, MPH, dismantling 3 persistent misconceptions about prostate health and the regulation of testosterone therapy.

The belief that testosterone fuels prostate cancer rests on authority and intuitive logic rather than evidence, and the FDA’s proposed revisions now reflect that. Morgentaler explains that a Nobel laureate’s conclusion went unchallenged for decades. It was reinforced by the assumption that if lowering testosterone helps advanced disease, raising it must cause harm. With the contraindication proposed to narrow to metastatic disease, he argues that observational data after prostatectomy, radiation, and active surveillance support treatment regardless of prostate cancer history. Khera notes that the American Urological Association guideline has advised since 2018 that testosterone therapy does not increase prostate cancer risk.

Bernie explains that prostate-specific antigen (PSA) depends on testosterone. Low testosterone can therefore falsely lower PSA, and restoration may raise it without signaling disease. Her own data in men treated for high-risk disease show no increase in biochemical recurrence with therapy. She joins Amy M. Pearlman, MD, in urging clinicians to check testosterone whenever PSA is measured.

Khera then calls the label’s warning that testosterone may worsen benign prostatic hyperplasia symptoms a theoretical concern, noting that TRAVERSE found no such effect. He also makes the case for descheduling, arguing that Schedule III status adds administrative burden and stigma without curbing misuse, which typically occurs outside the pharmacy. Bernie adds that scheduling discourages physicians from prescribing, steering men toward clinics that may not evaluate or monitor them appropriately.

Clinicians can now counsel men with prostate concerns from an evidence base, interpreting PSA alongside testosterone rather than reading either in isolation.

In the next episode, ‘Treatment Targets, Formulations, and the Future of Testosterone,’ panelists will answer audience questions on defining treatment success and choosing among formulations, and share their outlook for the field.


Related to this article